Bluemtech Q2 Results Soar 78% YoY

Blue M Tech garnered market attention by achieving remarkable sales growth in Q2 2025. Consolidated sales for this quarter reached approximately KRW 45.7 billion, demonstrating an impressive surge of 78.3% year-on-year and 33.7% quarter-on-quarter. This outward growth is analyzed to be primarily driven by the explosive increase in demand for obesity treatments like Wegovy and the expansion of its online pharmaceutical distribution business. In terms of profitability, signs of positive change were observed. Although operating losses still continued at approximately KRW 800 million, the deficit significantly narrowed compared to the previous quarter, raising expectations for improved profitability. However, net profit for the period regrettably turned to a deficit, recording a loss of approximately KRW 2.5 billion. This is understood to be a temporary phenomenon, unrelated to the company's fundamental operating activities, largely reflecting valuation losses on derivative products (such as BWs) due to stock price increases. The outlook for the second half of the year is even brighter. With a significant proportion of seasonal sales led by influenza vaccines and the expected acceleration of growth in the obesity treatment market, particularly with Wegovy, sales growth is anticipated to gain further momentum. Blue M Tech plans to continuously secure new growth engines through diversified strategies, including acquiring new clients, strengthening membership, and differentiating delivery services. Furthermore, in the second half, the company plans to implement management strategies focused on solidifying its foundation by emphasizing cost efficiency and expanding sales of key products. As Blue M Tech lays the groundwork for profitability improvement alongside outward growth, attention is drawn to its future trajectory.